



PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 56177

Title: Clinical efficacy of tocilizumab treating severe and critical patients with COVID-19

Reviewer’s code: 02856117

Position: Peer Reviewer

Academic degree: FACC, MBBS, PhD

Professional title: Associate Professor, Doctor, Research Fellow, Research Scientist, Senior Scientist

Reviewer’s Country/Territory: Greece

Author’s Country/Territory: China

Manuscript submission date: 2020-05-08

Reviewer chosen by: AI Technique

Reviewer accepted review: 2020-05-10 11:07

Reviewer performed review: 2020-05-27 10:02

Review time: 16 Days and 22 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

The topic of COVID-19 in this study is very hot. I read this manuscript carefully with interest. The inclusion and exclusion criteria are acceptable. Results are very interesting. As the COVID-19 is global pandemic disease, the results of this manuscript can be used as a reference for clinical treatment of COVID-19. Some minor language polishing should be corrected before final publication. Thank you.



PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 56177

Title: Clinical efficacy of tocilizumab treating severe and critical patients with COVID-19

Reviewer's code: 02823028

Position: Peer Reviewer

Academic degree: MBBS, MD

Professional title: Associate Professor, Research Associate

Reviewer's Country/Territory: Swaziland

Author's Country/Territory: China

Manuscript submission date: 2020-05-08

Reviewer chosen by: AI Technique

Reviewer accepted review: 2020-05-10 11:08

Reviewer performed review: 2020-06-03 00:18

Review time: 23 Days and 13 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

Very hot topic. This manuscript is very well written. In this study, the authors analyzed the clinical data of 19 severe and critical patients with COVID-19 who were treated with tocilizumab, and analyzed the effect of tocilizumab in inhibiting COVID-19 cytokine storm and provide theoretical reference for the clinical treatment of severe patients with COVID-19. The design of this study is reasonable, and the results are very interesting. The inclusion and exclusion criteria are clearly and acceptable. The CT images are good, and the data in the tables are very informative. As many papers have been published about COVID-19, the references should be checked and updated. And some minor language polishing should be corrected.



PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 56177

Title: Clinical efficacy of tocilizumab treating severe and critical patients with COVID-19

Reviewer's code: 05266764

Position: Peer Reviewer

Academic degree: MD, PhD

Professional title: Associate Professor

Reviewer's Country/Territory: Japan

Author's Country/Territory: China

Manuscript submission date: 2020-05-08

Reviewer chosen by: AI Technique

Reviewer accepted review: 2020-05-10 11:07

Reviewer performed review: 2020-06-03 00:23

Review time: 23 Days and 13 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

Very interesting study about the clinical efficacy of tocilizumab in the treatment of COVID-19. This study is very interesting. Although only 19 patients were included, the results give us some interesting information. Further research with more samples will be helpful. Anyway, I recommend to accept this manuscript after a minor language editing.